Drug

Ribavirin

Regulatory activity · EMA

ClassInosine-5'-monophosphate dehydrogenase 1 inhibitorActively researchedLate-stage developmentCooling momentum

Also known as Copegus, Moderiba, RBV, RTCA+10 more

Copegus, Moderiba, RBV, RTCA, Rebetol, RibaTab, Ribasphere, Tribavirin, Virazole, Ribavirina, Ribavirine, 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, Ribavirinum.

RxNorm9344 ChEMBLCHEMBL1643 ATCJ05AP01UNII49717AWG6K

Research papers

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever in West African Countries

Clinical trial2026-02-04Results expected Q2 2027 · ClinicalTrials.gov

A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever: A Double-blind, Randomized Control Trial

Clinical trial2025-05-29Completed · ClinicalTrials.gov

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Clinical trial2024-08-29Terminated · ClinicalTrials.gov

A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Clinical trial2024-08-20Results posted · ClinicalTrials.gov

Market withdrawal: Rebetol (EMA)

Regulatory2023-10-18EMA

A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment-naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b

Clinical trial2023-08-29Results posted · ClinicalTrials.gov

Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

Clinical trial2023-07-14Results posted · ClinicalTrials.gov

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.

Research2020-04-10Journal of medical virology

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.

Research2019-05-06Journal of viral hepatitis

Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.

Research2018-11-17Hepatology (Baltimore, Md.)

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.

Research2018-03-14Journal of viral hepatitis

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ribavirin

Aliases & brands

CopegusModeribaRBVRTCARebetolRibaTabRibasphereTribavirinVirazoleRibavirinaRibavirine1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamideRibavirinum

RxNorm CUI

9344

ChEMBL ID

CHEMBL1643

ATC codes

J05AP01

UNII

49717AWG6K

Primary mechanism

Inosine-5'-monophosphate dehydrogenase 1 inhibitor

Regulatory jurisdictions

ema

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Inosine-5'-monophosphate dehydrogenase 1

IMPDH1 · P20839

INHIBITORInosine-5'-monophosphate dehydrogenase 1 inhibitor

RNA-directed RNA polymerase

NS5b · O39930

INHIBITORRNA-directed RNA polymerase inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2023-10-18Market withdrawalMarket

Market withdrawal: Rebetol (EMA)

Indication: Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. Rebetol is indicated in combination with other… Show full indication

Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.